What are the recommended measures to lower low‑density lipoprotein (LDL) cholesterol in adults?

Measures to Lower LDL Cholesterol

Therapeutic lifestyle changes (TLC) combined with statin therapy form the foundation of LDL-lowering treatment, with specific LDL-C targets and medication intensity determined by cardiovascular risk category.

Risk-Based Treatment Algorithm

Step 1: Determine Risk Category and LDL-C Target

Very High Risk (established ASCVD, multiple major events, or diabetes with multiple risk factors):

• Target: LDL-C <70 mg/dL (1.8 mmol/L) 1, 2, 3
• For patients with established CVD or multiple risk factors: LDL-C <55 mg/dL (1.4 mmol/L) 3
• Start high-intensity statin immediately, even if LDL-C is already <100 mg/dL 1, 2

High Risk (diabetes age ≥40, or 10-year ASCVD risk ≥7.5%):

• Target: LDL-C <100 mg/dL (2.6 mmol/L) 1, 4
• Initiate statin therapy simultaneously with lifestyle changes if LDL-C ≥100 mg/dL 4

Moderately High Risk (≥2 risk factors, 10-year risk 10-20%):

• Target: LDL-C <130 mg/dL, with optional target <100 mg/dL 1, 2

Primary Severe Hypercholesterolemia (LDL-C ≥190 mg/dL):

• Target: ≥50% LDL-C reduction 5
• High-intensity statin required regardless of age or risk calculation 5

Step 2: Implement Therapeutic Lifestyle Changes (TLC)

Dietary Modifications (essential for all risk categories):

• Saturated fat: <7% of total energy intake 6, 7
• Dietary cholesterol: <200 mg/day 6, 7
• Trans-unsaturated fatty acids: minimize intake 6, 7
• Replace saturated fats with either carbohydrates or monounsaturated fats 6

Enhanced LDL-Lowering Dietary Options:

• Plant stanols/sterols: 2 g/day 6, 7
• Viscous (soluble) fiber: 10-25 g/day 6, 7

Weight and Physical Activity:

• Weight loss if overweight/obese (10% reduction in first year) 8
• ≥30 minutes moderate-intensity physical activity on most days 8
• Regular physical activity reduces triglycerides and improves insulin sensitivity 6, 7

Step 3: Initiate Statin Therapy

High-Intensity Statins (achieve ≥50% LDL-C reduction):

• Atorvastatin 40-80 mg or rosuvastatin 20-40 mg 5
• Use in: Very high-risk patients, established ASCVD, LDL-C ≥190 mg/dL, diabetes with ≥7.5% 10-year risk 3, 5

Moderate-Intensity Statins (achieve 30-40% LDL-C reduction):

• Use when high-intensity contraindicated or not tolerated 1, 2
• Minimum intensity for high-risk and moderately high-risk patients should achieve 30-40% LDL-C reduction 1, 2

Special Populations:

• Diabetes patients ≥40 years: statin therapy regardless of baseline LDL-C 4, 3
• Type 1 diabetes ≥40 years or >20 years duration: statin therapy 3
• Chronic kidney disease stages 1-4: statin therapy irrespective of risk score 3

Step 4: Add Non-Statin Therapy When Needed

If LDL-C remains ≥70 mg/dL on maximally tolerated statin in very high-risk patients:

1. Add ezetimibe first 9

   • Reduces LDL-C additional ~20%
   • Proven to reduce cardiovascular events by 2 percentage points in very high-risk patients 9

2. Add PCSK9 inhibitor if still above target 3, 9

   • Reduces LDL-C additional 50-60% 10
   • Proven to reduce ASCVD events by ~15% over 3 years 9
   • Consider when LDL-C remains ≥70 mg/dL despite statin + ezetimibe 9

For elevated triglycerides (≥200 mg/dL) with low HDL-C:

• Consider adding fibrate or nicotinic acid to statin therapy 1, 2
• For diabetes patients on statin at LDL goal with triglycerides >150 mg/dL and ≥2 additional risk factors: add eicosapentaenoic acid ethyl ester 4 g/day 3

Step 5: Monitor and Adjust

Lipid Testing Frequency:

• Adults with diabetes or high risk: test annually 4
• Low-risk patients with optimal values: every 2 years 4
• After medication changes: recheck in 4-12 weeks to assess response 1

Critical Implementation Points

Common Pitfalls to Avoid:

• Do not delay statin initiation in very high-risk patients waiting for lifestyle changes alone 4
• Do not use ethnicity to modify LDL-C goals 1, 2
• Do not stop monitoring once target achieved—maintain "lower for longer" 11
• In patients >75 years with ASCVD, continue statin if tolerating it 5

Key Nuances: The most recent high-quality evidence from the 2020 Endocrine Society guideline 3 and 2019 AHA/ACC update 9 emphasizes more aggressive LDL-C lowering (<70 mg/dL for very high risk, <55 mg/dL for established CVD) compared to older ATP III guidelines 1, 2. The principle of "lower for longer is better" is now firmly established 11, with combination therapy (statin + ezetimibe ± PCSK9 inhibitor) increasingly necessary to achieve these intensive targets in highest-risk patients.

For patients with very high triglycerides (≥1000 mg/dL): Restrict all dietary fat and initiate lipid-lowering medication immediately to prevent pancreatitis 6, 7. Fish oil supplementation may help but requires LDL-C monitoring as it can increase LDL-C 6, 7.